Skip to main content
    P

    Pasithea Therapeutics Corp (KTTA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.50
    -0.02 (-4.21%)

    Market Cap: $17.44M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Pasithea Therapeutics Corp (KTTA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Pasithea Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$20.43M, operating cash flow was -$15.21M and free cash flow was -$15.21M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$6.58M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $20.86M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$15.06KN/A-14.7%-29925.7%-14430.5%
    Dec 2020N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Revenue$0$0$0$0$15.06KN/A
    Cost of revenue$0$0$0$0$17.27KN/A
    Gross profit$0$0$0$0-$2.21KN/A
    Research and development$7.98M$7.20M$8.10M$2.67M$0$0
    Operating income-$20.86M-$14.25M-$15.98M-$12.59M-$4.51M-$61.48K
    Net income-$20.43M-$13.90M-$15.96M-$13.94M-$2.17M-$61.48K
    EBITDA-$20.09M-$13.68M-$15.27M-$10.87M-$2.17M-$40.98K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$649.03K$0$0$0$976.31K
    Gross profit$0$0$0-$157.96K$0$0$0-$162.26K$0$0$0-$162.22K
    Operating income-$6.97M-$5.71M-$4.88M-$10.26M-$3.11M-$3.81M-$3.68M-$3.26M-$3.00M-$3.95M-$4.04M-$5.15M
    Net income-$6.58M-$5.27M-$2.87M-$10.11M-$3.04M-$3.72M-$3.56M-$3.18M-$3.00M-$3.87M-$3.86M-$5.05M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $55.16M were 91.6% of total assets of $60.24M, against total liabilities of $5.02M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$60.24M$16.06M$26.12M$45.18M$53.32M$247.96K
    Current assets$56.46M$7.37M$16.69M$34.08M$53.30M$247.96K
    Cash and equivalents$55.16M$6.92M$16.33M$33.09M$52.97M$243.65K
    Total liabilities$5.02M$1.28M$2.72M$2.68M$1.90M$6.60K
    Short-term debtN/AN/A$81.68K$160.36KN/AN/A
    Shareholder equity$55.22M$14.78M$23.40M$42.50M$51.42M$241.35K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$46.49M$51.71M$56.35M$60.24M$13.63M$17.01M$14.66M$16.06M$18.64M$17.66M$22.41M$26.12M
    Total liabilities$2.76M$1.87M$1.54M$5.02M$1.42M$1.83M$1.68M$1.28M$823.98K$1.49M$2.52M$2.72M
    Cash and equivalents$41.22M$45.66M$50.40M$55.16M$4.12M$7.22M$5.34M$6.92M$9.36M$7.97M$12.01M$16.33M
    Shareholder equity$43.73M$49.84M$54.81M$55.22M$12.21M$15.18M$12.98M$14.78M$17.81M$16.18M$19.88M$23.40M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$15.21M-$13.92M-$13.43M-$11.89M-$3.17M-$38.69K
    Capital expenditures$0$2$34.30K$107.10K$21.50K$1
    Free cash flow-$15.21M-$13.92M-$13.46M-$12.00M-$3.20M-$38.69K
    Dividends paidN/A$359.66MN/AN/AN/AN/A
    Share repurchasesN/AN/A$3.73M$3.21M$27.17MN/A
    Investing cash flow$11.00K$0$399.01K-$2.30M-$21.50K-$21.50K
    Financing cash flow$63.52M$4.52M-$3.73M-$3.21M$55.93M$282.34K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$4.48M-$4.71M-$4.79M-$5.40M-$2.89M-$3.87M-$3.06M-$2.44M-$3.12M-$4.04M-$4.32M-$3.31M
    Capital expendituresN/AN/A$0$2$5$4$3$4$1$5$5$36
    Free cash flowN/AN/A-$4.79M-$5.40M-$2.89M-$3.87M-$3.06M-$2.44M-$3.12M-$4.04M-$4.32M-$3.31M
    Last 12 quarters

    Frequently Asked Questions About KTTA

    What is Pasithea Therapeutics' annual revenue?

    Pasithea Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Pasithea Therapeutics profitable?

    No. Pasithea Therapeutics reported net income of -$20.43M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does KTTA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$15.21M minus capital expenditures of $0 produced free cash flow of -$15.21M.

    How much debt does Pasithea Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $55.16M.